Bolt Biotherapeutics, Inc.
BOLTNASDAQHealthcare● Active
$4.59
+$0.03(+0.66%)
Market Cap$8819993
P/E Ratio—
52W High$7.35
52W Low$3.91
Bolt Biotherapeutics, Inc. (BOLT) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BOLT · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 12, 2026EPS Actual
-$4.31
Est. -$2.85 · -51.2%
Revenue
$0.00B
Est. $0.00B · -98.3%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 12, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
BOLT reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 13, 2026 | -$3.39 | — | — | — | $0.00B | — |
| ▼ Q2 FY2026 | May 12, 2026 | -$2.85 | -$4.31 | -51.2% | $0.00B | $0.00B | -98.3% |
| ▲ Q1 FY2026 | Mar 12, 2026 | -$4.30 | -$3.84 | +10.7% | $0.00B | $0.00B | +275.0% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$5.07 | -$3.72 | +26.6% | $0.00B | $0.00B | +164.3% |
| ▲ Q3 FY2025 | Aug 14, 2025 | -$6.40 | -$4.46 | +30.3% | $0.00B | $0.00B | +113.3% |
| ▲ Q2 FY2025 | May 12, 2025 | -$6.80 | -$5.80 | +14.7% | $0.00B | $0.00B | +59.2% |
| — Q1 FY2025 | Mar 24, 2025 | -$7.60 | -$7.60 | +0.0% | $0.00B | $0.00B | -98.7% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.36 | -$0.40 | -11.1% | $0.00B | $0.00B | +44.4% |
Q3 FY2026
Aug 13, 2026
EPS Actual
—
EPS Est.
-$3.39
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 12, 2026Miss
EPS Actual
-$4.31
EPS Est.
-$2.85
EPS Surpr.
-51.2%
Revenue
$0.00B
Q1 FY2026
Mar 12, 2026Beat
EPS Actual
-$3.84
EPS Est.
-$4.30
EPS Surpr.
+10.7%
Revenue
$0.00B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$3.72
EPS Est.
-$5.07
EPS Surpr.
+26.6%
Revenue
$0.00B
Q3 FY2025
Aug 14, 2025Beat
EPS Actual
-$4.46
EPS Est.
-$6.40
EPS Surpr.
+30.3%
Revenue
$0.00B
Q2 FY2025
May 12, 2025Beat
EPS Actual
-$5.80
EPS Est.
-$6.80
EPS Surpr.
+14.7%
Revenue
$0.00B
Q1 FY2025
Mar 24, 2025
EPS Actual
-$7.60
EPS Est.
-$7.60
EPS Surpr.
+0.0%
Revenue
$0.00B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$0.40
EPS Est.
-$0.36
EPS Surpr.
-11.1%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-6.80 | $-6.80 | $-6.80 | 1 |
| Q3 FY2027 | $-1.40 | $-1.40 | $-1.40 | 1 |
| Q2 FY2027 | $-2.20 | $-2.20 | $-2.20 | 1 |
| Q1 FY2027 | $-2.00 | $-2.00 | $-2.00 | 1 |
| Q4 FY2026 | $-3.18 | $-3.18 | $-3.18 | 1 |
| Q3 FY2026 | $-3.20 | $-3.20 | $-3.20 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 12, 2026 | -51.2% | $4.70 | $4.78 | +1.70% |
| ▲ Q1 FY2026 | Mar 12, 2026 | +10.7% | $4.13 | $4.05 | -1.94% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +26.6% | $4.81 | $4.69 | -2.49% |
| ▲ Q3 FY2025 | Aug 14, 2025 | +30.3% | $5.62 | $5.44 | -3.20% |
| ▲ Q2 FY2025 | May 12, 2025 | +14.7% | $7.16 | $7.40 | +3.35% |
| ▲ Q1 FY2025 | Mar 24, 2025 | +0.0% | $8.78 | $8.75 | -0.34% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -11.1% | $12.72 | $12.84 | +0.94% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -3.7% | $14.02 | $14.00 | -0.14% |
Q2 FY2026+1.70%
Report Date
May 12, 2026
EPS Beat/Miss
-51.2%
Price Before
$4.70
Price After
$4.78
Q1 FY2026-1.94%
Report Date
Mar 12, 2026
EPS Beat/Miss
+10.7%
Price Before
$4.13
Price After
$4.05
Q4 FY2025-2.49%
Report Date
Nov 12, 2025
EPS Beat/Miss
+26.6%
Price Before
$4.81
Price After
$4.69
Q3 FY2025-3.20%
Report Date
Aug 14, 2025
EPS Beat/Miss
+30.3%
Price Before
$5.62
Price After
$5.44
Q2 FY2025+3.35%
Report Date
May 12, 2025
EPS Beat/Miss
+14.7%
Price Before
$7.16
Price After
$7.40
Q1 FY2025-0.34%
Report Date
Mar 24, 2025
EPS Beat/Miss
+0.0%
Price Before
$8.78
Price After
$8.75
Q4 FY2024+0.94%
Report Date
Nov 12, 2024
EPS Beat/Miss
-11.1%
Price Before
$12.72
Price After
$12.84
Q3 FY2024-0.14%
Report Date
Aug 13, 2024
EPS Beat/Miss
-3.7%
Price Before
$14.02
Price After
$14.00
Avg Beat Reaction-0.92%
Avg Miss Reaction+0.83%
Beat Rate5 / 8 quarters
Largest Move+3.35% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BOLT ends December
Bolt Biotherapeutics, Inc. (BOLT) most recently reported earnings on May 12, 2026 for Q2 FY2026, posting EPS of $-4.31 — missing the analyst consensus of $-2.85 by -51.2%. The next BOLT earnings date is expected around September 1, 2026.
Each quarter, investors track BOLT earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BOLT revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BOLT's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BOLT earnings · 5 questionsBolt Biotherapeutics, Inc.'s next earnings report is expected around September 1, 2026. BOLT typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BOLT historically reports after market close (AMC).
BOLT earnings datewhen is BOLT earningsBOLT next earnings datewhen does BOLT report earningsBOLT earnings calendar
▸ Source: FMP · Bolt Biotherapeutics, Inc. SEC filings · US GAAP · Bolt Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026